Galectin-3 - a modern biomarker for the diagnosis of left ventricular hypertrophy and chronic heart failure and control of treatment of patients with hypertension

  • V. O. Ruzhanska National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V. G. Sivak National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • T. V. Polishchuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V. M. Zhebel National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: hypertonic disease, left ventricular hypertrophy, chronic heart failure, galectin-3.


The development of new methods for the prevention and treatment of chronic heart failure and its control is an urgent medical and social problem. In this regard, using of new biological markers of the disease may be useful for early diagnosis of the disease, predict a clinical course, monitor the effects of pharmacotherapy (personalized medicine) and play an important role in stratifying the patient's risk. In 2013, according to the recommendation of the American Heart Association, a galectin-3 was introduced into the pool of such biomarkers for prevention and treatment of chronic heart failure. Objective: to improve prediction of the course and effectiveness of the therapy for hypertension and chronic heart failure as the hypertension complication in men 40-60 years old by applying the level of galectin-3 as a biomarker. There were observed the men 40-60 years old with hypertension and chronic heart failure for the concentration of galectin-3. Also, there were observed subjects without cardiovascular pathology (n=79), the men with hypertonic disease with myocardial hypertension (n=62) and the men with chronic heart failure II-III functional class of NYHA (n=50) for the indicators of central and systemic hemodynamics. The level of galectin-3 was determined by immunoassay analysis on the equipment "Stat Fact 300". Structural and functional parameters of myocardium were assessed by an ultrasound method using the equipment "RADMIR ULTIMARA". Data statistical analysis was performed on a personal computer using standard statistical package "Statistica 10.0". All data is presented in the form of average (M) and standard deviation (± σ). It has been established that the concentration of galectin-3 significantly decreases against the background of treatment. The level of galectin-3 in the patients with the II stage of hypertonic disease with good treatment effect was close to normal values compared to those with moderate treatment effect. In terms of patients with hypertension III stage, the level of galectin-3 also decreased, indicating the possibility of therapy monitoring using this biomarker. The mathematical model of the galectin-3 influencing factors also has been determined in patients with hypertension. The boundary level of the galectin-3 has been calculated, it is counted 46.51 pg/ml. It might be assumed a moderate effect of the treatment of hypertensive patients and chronic heart failure in males.


[1] Antomonov, M. Yu. (2004). Calculation of threshold (critical) levels of existing accounting factors for different types of data obtained in hygienic studies. Hygiene of settlements. 43, 573-579.
[2] Berezin, A. E. (2017). Biomarkers in Heart Failure. J. Blood Lymph., 7(3), 172-179. doi: 10.4172/2165-7831.1000172
[3] Chen, A., Hou, W., Zhang, Y., Chen, Y., & He, B. (2015). Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int. J. Cardiol., 1(182), 168-170. doi: 10.1016/j.ijcard.2014.12.137
[4] Chistic, T. V. (2016). An integrated approach to the treatment of disorders of cerebral circulation. Medicine of emergency, 7, 66-74.
[5] Daghar, S. (2017). The diagnostic value of the level of galectin-3 in patients with hypertrophic cardiomyopathy. Scientific Journal “ScienceRise: Medical Science”, 4(12), 13-18. doi: 10.15587/2519-4798.2017.99566
[6] De Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009). Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart. Fail., 11, 811-817. doi: 10.1093/eurjhf/hfp097
[7] De Boer, Yu, L. & van Veldhuisen, D. J. (2010). Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep., 7(1), 1-8. doi: 10.1007/s11897-010-0004-x
[8] De Boer, R. A., Edelmann, F., Cohen-Solaal, A., Mamas, A., Maisel A., & Pieske B. (2013). Galectin-3 in heart failure with preserved ejection fraction. European Journal of Heart Failure,15, 1095-1101. doi: 10.1093/eurjhf/hft077
[9] Ertl, G. & Ruschitzka, F. (2014). The Year in Cardiology 2013: heart failure. Eur. Heart J., 35(7), 470-473. doi: 10.1093/eurheartj/eht555.
[10] Fedkov, S.V. (2015). European strategy for the diagnosis of ischemic heart disease using non-invasive visualization methods. Radiology, radiation therapy, 1-2, 101-112.
[11] Hrynchyshyn, N., Jourdain, P., Desnos, M., Diebold, B. & Funck, F. (2013). Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch. Cardiovasc. Dis., 106(10), 541-546. doi: 10.1016/j.acvd.2013.06.054
[12] Іgnatenko, G. A., Mukhin, I. V. & Bashkirtsev, A. V. (2012). Pathological remodeling of left ventricular myocardium in patients with arterial hypertension with concomitant ischemic heart disease. Ecological problems of experimental and clinical medicine, 6, 520-527.
[13] Jennifer, E., Chunyu Liu, Asya Lyass, Paul Courchesne & Daniel Levy. (2012). Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. J. Am. Coll. Cardiol., 60(14), 1249-1256. doi: 10.1016/j.jacc.2012.04.053
[14] Karatolios, K., Chatzis, G., Holzendorf, V., Stork, S, Richter, А…Pankuweit, S. (2018). Galectin-3 as a predictor of left ventricular reverse remodeling in recent-onset dilated cardiomyopathy. Desease markers, 1-7. doi: 10.1155/2018/2958219
[15] Kovalenko, V. M., Kornatsky, V. M., Dorogoy, A. P. & Sirenko, Yu. M. (2014). Diseases of the circulatory system as a medical and social and socio-political problem. Kiev: National Academy of Medical Sciences of Ukraine, State Institution "National Science Center" Institute of Cardiology. M. D. Strazhesko".
[16] Kovalenko, V. M., Kornatsky, V. M. & Manoilenko, T. S. (2016). Problems of health and medical care and the model of improvement in modern conditions. Kiev: National Academy of Medical Sciences of Ukraine, State Institution "National Science Center" Institute of Cardiology. M. D. Strazhesko".
[17] Kubanek, M., Sramko, M., Maluskova, J., Kautznerova, D. & Kautzner, J. (2013). Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J. Am. Coll. Cardiol., 61(1), 54-63. doi: 10.1016/j.jacc.2012.07.072.
[18] Lok, D. J., Van Der Meer, P., de la Porte, P. W., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., & van Veldhuisen, D. J. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol., 99(5), 323-328. doi: 10.1007/s00392-010-0125-y.
[19] Lupu, A., Lupu, S., & Agoston-Coldea, L. (2018). Is galectin-3 a promoter of ventricular dysfunction? Revista Romana de Medicina de Laborator, 26(1), 21-36. doi: 10.2478/rrlm-2018-0001
[20] McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., … ESC Committee for Practice Guidelines. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart. J., 33(14), 1787-1847. doi: 10.1093/eurheartj/ehs104
[21] Mikitey, O. N. (2015). Features of development of risk factors in patients with recurrent ischemic stroke. Eastern European neurological journal, 2, 27-30.
[22] Ponikowski, P., Voors, A. A., Anker, S. D., Ruschitzka, F., Rutten, F. H., van der Meer, P., … ESC Scientific Document Group (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 128, 1-85. doi: 10.1093/eurheartj/ehw128
[23] Radchenko, G. D., & Sirenko, Yu. M. (2010). Left ventricular hypertrophy: definition, evaluation methods, regression possibilities. Arterial hypertension. 4(12), 1-10.
[24] Tseluyko, V. Y., Matviychuk, N. V. & Kinoshenko, K. Yu. (2014). Galectin-3 in patients with chronic heart failure. Ukrainian Cardiology Magazine, 3, 77-81.
[25] Tseluyko, V. Y., Yakovleva, L. M. & Matuzok, O. E. (2017). Clinical and anamnestic characteristics and indicators of intracardiac hemodynamics in patients with acute myocardial infarction depending on the polymorphism of T (-786C) endothelial NO synthase gene. Heart and blood vessels, 2, 46-52.
[26] Van Vark, L. C., Lesman-Leegte, I., Baart, S. J., Postmus, D., Pinto, Y. M., de Boer, R.A., … TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with Heart Failure) Investigators (2017). Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J. Am. Heart Assoc., 6(12), 1-12. doi: 10.1161/JAHA.116.003700
[27] Wermelt, J. A. & Schunkert, H. (2017). Management of arterial hypertension. Herz, 42(5), 515-526. doi: 10.1007/s00059-017-4574-1
[28] Wu, C. K., Su, M. Y., Lee, J. K., Chiang, F. T., Hwang, J-J., Lin, J.-L., … Tsai, C. T. (2015). Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci. Rep., 5, 17007. doi: 10.1038/srep17007
[29] Zhebel, V. M., Sakovich, O. O., Vilchinsky, G. V., & Singkh, O. O. (2012). Method of diagnosis of chronic heart failure in postmenopausal women with hypertension. Pat. 67486 Україна, Ukraine. MPK G01N 33/48 (2006.01).
[30] Zhong, X., Qian, X., Chen, G., & Song, X. (2018). The role of galectin-3 in heart failure and cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 46 (3), 197-203. doi: 10.1111/1440-1681.13048
How to Cite
Ruzhanska, V. O., Sivak, V. G., Polishchuk, T. V., & Zhebel, V. M. (2018). Galectin-3 - a modern biomarker for the diagnosis of left ventricular hypertrophy and chronic heart failure and control of treatment of patients with hypertension. Biomedical and Biosocial Anthropology, (33), 30-35.